Brief: Neurizon Therapeutics Posts Loss For Year Attributable A$16.6 Million
26/08/2025 02:32
Aug 26 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX: LOSS FOR YEAR ATTRIBUTABLE A$16.6 MILLION Further company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility